Keros Therapeutics (KROS) Price & Analysis

Compare

346 Followers

KROS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.12 - $72.37

Previous CloseN/A

Volume109.28K

Average Volume (3M)450.71K

Market Cap

$584.46M

Enterprise Value-$284.12M

Total Cash (Recent Filing)$720.54M

Total Debt (Recent Filing)$18.41M

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Oct 30, 2025

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding40,615,414

10 Day Avg. Volume399,090

30 Day Avg. Volume450,706

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.49

Enterprise Value/Revenue-1.32

Enterprise Value/Gross Profit-1.33

Enterprise Value/Ebitda93.52

Forecast

1Y Price Target

$24.17

Price Target Upside65.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Capital ReturnKeros announced plans to return $375 million in excess capital to shareholders, which could help improve investor sentiment.

Cost ManagementKeros announced a headcount reduction, which is expected to result in potential annual savings of ~$17 million.

Strategic PartnershipKeros announced an exclusive agreement with Takeda to further develop, manufacture, and commercialize elrit worldwide.

Bears Say

Clinical Study ChallengesManagement announced the decision to halt all dosing and terminate the study early due to observation of pericardial effusion events.

Future OutlookThe future outlook for cibo appears uncertain at this point.

Investor SentimentSentiment remains negative, possibly weighing on the share outlook, with investor frustrations from past disappointments still top of mind.

Keros Therapeutics News

Keros Therapeutics to discontinue cibotercept, announces COO departure

Keros Therapeutics (KROS) announced a strategic realignment designed to reallocate resources towards the development of its key clinical...

1d ago

KROS

Keros Therapeutics reports Q2 EPS (76c), consensus ($1.13)

Reports Q2 revenue $18.17M, consensus $4.21M. “The second quarter marked an important point for Keros, as Keros’ Board...

2d ago

KROS

Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial

Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 3 RENEW clinical trial of...

22d ago

TAK

KROS

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Keros Therapeutics. The associated price target...

9h ago

KROS

Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks

Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Corporate Activity and Growth category. Keros Therapeutics,...

13h ago

KROS

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments

In a report released today, Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics, with a...

1d ago

KROS

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation

TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating...

2d ago

KROS

Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating

William Blair analyst Matt Phipps has maintained their neutral stance on KROS stock, giving a Hold rating on...

2d ago

KROS

Keros Therapeutics Announces Strategic Realignment and Leadership Changes

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On August 6, 2025, Keros Therapeutics announced a strategic...

2d ago

KROS

Keros Therapeutics Begins Phase 3 Trial for Elritercept

Keros Therapeutics ( ($KROS) ) has provided an update. On July 17, 2025, Keros Therapeutics announced the dosing...

22d ago

KROS

Keros Therapeutics Announces CMO Resignation

Keros Therapeutics ( ($KROS) ) has issued an update. On July 9, 2025, Keros Therapeutics announced the resignation...

24d ago

KROS

McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AUB

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Keros Therapeutics (KROS...

2M ago

KROS

Keros Therapeutics downgraded to Neutral from Buy at BofA

BofA analyst Jason Zemansky downgraded Keros Therapeutics (KROS) to Neutral from Buy with a price target of $18,...

2M ago

KROS

KROS FAQ

What was Keros Therapeutics, Inc.’s price range in the past 12 months?

Keros Therapeutics, Inc. lowest stock price was $9.12 and its highest was $72.37 in the past 12 months.

What is Keros Therapeutics, Inc.’s market cap?

Keros Therapeutics, Inc.’s market cap is $584.46M.

When is Keros Therapeutics, Inc.’s upcoming earnings report date?

Keros Therapeutics, Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.

How were Keros Therapeutics, Inc.’s earnings last quarter?

Keros Therapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$1.11 by $0.35.

Is Keros Therapeutics, Inc. overvalued?

According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Keros Therapeutics, Inc. pay dividends?

Keros Therapeutics, Inc. does not currently pay dividends.

What is Keros Therapeutics, Inc.’s EPS estimate?

Keros Therapeutics, Inc.’s EPS estimate is -1.05.

How many shares outstanding does Keros Therapeutics, Inc. have?

Keros Therapeutics, Inc. has 40,615,414 shares outstanding.

What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?

Keros Therapeutics, Inc. reported an EPS of -$0.76 in its last earnings report, beating expectations of -$1.11. Following the earnings report the stock price went down -7.287%.

Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?

Currently, no hedge funds are holding shares in KROS

Keros Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

3.33%

Trailing 12-Months

Asset Growth

61.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's primary focus is on developing therapies that target the transforming growth factor-beta (TGF-β) family of proteins, which are implicated in various diseases. Keros Therapeutics' core products aim to treat conditions such as anemia, thrombocytopenia, and bone diseases by modulating these protein pathways to improve patient outcomes.

Keros Therapeutics (KROS) Earnings & Revenues

Historic Earnings Reports

KROS Stock 12 Month Forecast

Average Price Target

$24.17

▲(65.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","47":"$47","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21,34,47,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,15.910769230769231,17.501538461538463,19.092307692307692,20.683076923076925,22.273846153846154,23.864615384615384,25.455384615384617,27.046153846153846,28.636923076923075,30.22769230769231,31.818461538461538,33.40923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,15.077692307692308,15.835384615384616,16.593076923076925,17.35076923076923,18.10846153846154,18.866153846153846,19.623846153846156,20.38153846153846,21.13923076923077,21.896923076923077,22.654615384615386,23.412307692307692,{"y":24.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,14.372307692307693,14.424615384615384,14.476923076923077,14.52923076923077,14.581538461538461,14.633846153846154,14.686153846153847,14.73846153846154,14.79076923076923,14.843076923076923,14.895384615384616,14.947692307692307,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >